These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19708724)

  • 21. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
    de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
    Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agomelatine: a novel pharmacological approach to treating depression.
    Owen RT
    Drugs Today (Barc); 2009 Aug; 45(8):599-608. PubMed ID: 19927226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.
    Montgomery SA; Kasper S
    Int Clin Psychopharmacol; 2007 Sep; 22(5):283-91. PubMed ID: 17690597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.
    Heun R; Ahokas A; Boyer P; Giménez-Montesinos N; Pontes-Soares F; Olivier V;
    J Clin Psychiatry; 2013 Jun; 74(6):587-94. PubMed ID: 23842010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoring circadian rhythms: a new way to successfully manage depression.
    Gorwood P
    J Psychopharmacol; 2010 Aug; 24(2 Suppl):15-9. PubMed ID: 20663804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
    Lôo H; Hale A; D'haenen H
    Int Clin Psychopharmacol; 2002 Sep; 17(5):239-47. PubMed ID: 12177586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agomelatine treatment of major depressive disorder.
    Dolder CR; Nelson M; Snider M
    Ann Pharmacother; 2008 Dec; 42(12):1822-31. PubMed ID: 19033480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
    Kennedy SH; Rizvi SJ
    CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agomelatine: AGO 178, AGO178, S 20098.
    Drugs R D; 2008; 9(3):177-83. PubMed ID: 18457470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agomelatine: innovative pharmacological approach in depression.
    Popoli M
    CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
    Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.
    Kennedy SH; Avedisova A; Belaïdi C; Picarel-Blanchot F; de Bodinat C
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):378-389. PubMed ID: 26708320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of agomelatine in depression: the evidence.
    den Boer JA; Bosker FJ; Meesters Y
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S21-4. PubMed ID: 16436936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
    Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    Englisch S; Jung HS; Lewien A; Becker A; Nowak U; Braun H; Thiem J; Eisenacher S; Meyer-Lindenberg A; Zink M
    J Clin Psychopharmacol; 2016 Dec; 36(6):597-607. PubMed ID: 27805978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
    Kennedy SH; Grouin JM; Cadour S; Robert V; Picarel-Blanchot F
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29327372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.